Interestingly, as mentioned in the previous paragraph, an interim analysis of an ongoing trial (NCT02544880), of anti-MUC1 vaccine with tadalafil, reported the combination to be well-tolerated in 14 eligible HNSCC patients of the 16 enrolled [55]. This evidence concerns the gene MUC1 and head and neck squamous cell carcinoma.